Contract Win
01 May 2014
Instem plc
("Instem" or the "Company")
Contract Win
Instem’s Provantis and Centrus solutions selected by WIL Research to replace and enhance its toxicology systems and processes worldwide
Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces today that it has been selected by WIL Research (“WIL”) as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites.
Key Facts
- Instem technology to replace all existing study management systems at WIL Research
- WIL Research selects all Provantis Preclinical Study Management modules
- Using Instem’s Centrus-submit solution, WIL Research will become SEND (Standard for Exchange of Nonclinical Data) enabled
- WIL Research to leverage Instem’s market leading SaaS model for worldwide deployment
WIL Research has approximately 1,200 staff offering a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.
WIL Research has chosen Instem’s entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem’s Toxicology Resource Planning (“TRP”) solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future.
WIL Research has additionally selected Instem’s Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.
David Spaight, Chief Executive Officer at WIL Research, commented: “We are delighted to announce our enhanced partnership with Instem on a global level to deploy a comprehensive solution for toxicology data collection and management across our facilities situated in the United States, the Netherlands and in France. By leveraging our existing experience with Provantis in France, this expanded platform will support growing demand from our clients requiring a common and seamless multi-site global study management solution.”
Phil Reason, CEO of Instem plc, commented: “WIL’s selection of Instem’s technology to replace all of its existing study management systems is a significant endorsement of the quality of our solutions. WIL has been a valued customer of Instem for 7 years and we are excited that it has chosen to extend that relationship as part of the technology-driven transformation that it is embarking upon. Instem has already secured SaaS revenues in excess of $2 million per annum and this provides further evidence of the attractiveness of this solution to clients. Demand for our offering remains strong and the growing proportion of SaaS contracts is leading to increasing visibility going forward.”For further information, please contact:
| Instem plc | www.instem.com |
| Phil Reason, CEO | +44 (0) 1785 825600 |
| Nigel Goldsmith, CFO | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Richard Lindley | |
| Nick Owen | |
| James White | |
| Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
| Paul Cornelius | or instem@walbrookpr.com |
| Sam Allen | |
| Helen Cresswell | |
| Paul Whittington |
About WIL Research
WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety and toxicological assessment research and services to the international pharmaceutical, biotechnology, chemical, agricultural, veterinary, food and consumer products industries.
Find out more about WIL Research at www.wilresearch.com
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.